Approval for the contak renewal 3 avt and contak renewal 3 avt he systems.  The systems are indicated for the following: contak renewal 3 avt cardiac resynchronization therapy defibrillators (crt-ds) are indicated for patients with moderate to severe heart failure (nyha iii/iv) who remain symptomatic despite stable, optimal heart failure drug therapy, and have left ventricular dysfunction (ef <= 35%) and qrs duration >= 120 ms. contak renewal 3 avt provides atrial antitachycardia pacing and atrial defibrillation treatment for patients with a history of or who are at risk of developing atrial arrhythmias.